Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa (HS2006)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00795574
Recruitment Status : Completed
First Posted : November 21, 2008
Last Update Posted : November 24, 2008
Information provided by:
Florida Academic Dermatology Centers

Brief Summary:
A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa

Condition or disease Intervention/treatment Phase
Hidradenitis Suppurativa Drug: infliximab Drug: Placebo Comparator Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa
Study Start Date : June 2005
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Infliximab

Arm Intervention/treatment
Experimental: infliximab
Double blind placebo cross-over
Drug: infliximab
Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.

Drug: Placebo Comparator
5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.

Placebo Comparator: Placebo
Double blind placebo controlled cross-over
Drug: Placebo Comparator
5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Person must have moderate to severe Hidradenitis suppurativa
  • Multiple ER or doctors visits related to HS
  • Intralesional kenalog injection >5/year, but none within 3 months of entry
  • HS >1 year duration
  • Failed systemic retinoids, but not within 3 months of entry
  • Failed at least one prior course of antibiotic therapy, which must not have been administered within 3 months of entry to the study (excluding the recommended antibiotic regimen given immediately before randomization for evidence of active infection
  • History of surgery (reconstructive), but not within 3 months of entry

Exclusion Criteria:

  • Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion (this includes father's who plan on fathering a child within 6 months after their last infusion
  • Known allergy against infliximab
  • Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic steroids (equal or less than 10 mg daily prednisolone or equivalent).
  • Have had any previous treatment with monoclonal antibodies or antibody fragments.
  • Have a known history of serious infections (eg, hepatitis, pneumonia or pyelonephritis) in the previous 3 months.
  • Have or have had an opportunistic infection (eg, herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.
  • Are considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules defined in Section 26 on: Tuberculosis Eligibility Assessment, Screening, and Early Detection of Reactivation Rules.
  • Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (eg, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly.
  • Currently have any known malignancy or have a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.
  • Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00795574

Layout table for location information
United States, Florida
Florida Academic Dermatology Center
Miami, Florida, United States, 33143
Sponsors and Collaborators
Florida Academic Dermatology Centers
Layout table for investigator information
Principal Investigator: Francisco A Kerdel, M.D Florida Acadecmic Dermatology Center

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Francisco A Kerdel,M.D., Florida Academic Dermatology Centers Identifier: NCT00795574    
Other Study ID Numbers: HS2006
First Posted: November 21, 2008    Key Record Dates
Last Update Posted: November 24, 2008
Last Verified: November 2008
Keywords provided by Florida Academic Dermatology Centers:
Hidradenitis Suppurativa
Additional relevant MeSH terms:
Layout table for MeSH terms
Hidradenitis Suppurativa
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents